The Ohio State University- Wexner Medical Center | Strategic Alliance Partners

The vascular neurosurgeon and professor of neurological surgery at The Ohio State University Wexner Medical Center spoke about advancements in stroke treatment, including endovascular thrombectomy and new drug therapies, that aim to address unmet need in patients. [WATCH TIME: 5 minutes]

The associate professor of neurology at The Ohio State University Wexner Medical Center provided insight on research assessing the use of a developed artificial intelligence/machine learning tool for automated stroke scale calculation. [WATCH TIME: 6 minutes]

New findings from a study presented at the 2024 ACTRIMS Forum revealed an increase in epigenetic age acceleration among a subgroup of patients with multiple sclerosis.

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center talked about the impact of ongoing seizures in patients with drug-resistant epilepsy and the importance of education for emerging opportunities in epilepsy care. [WATCH TIME: 3 minutes]

The division director of epilepsy and associate professor of neurology at The Ohio State University Wexner Medical Center discussed the profound repercussion of ongoing seizures for patients with epilepsy which is to be presented at AES 2023 in SK Life Science’s symposium. [WATCH TIME: 5 minutes]

The virtual care program built by The Ohio State University Wexner Medical Center allows for expanded access to patient care in rural areas, improved decision-making, and hands-on experience for young neurologists.

Lucretia Long, APRN-CNP, an associate clinical professor of neurology at OSU Wexner Medical Center, offered her perspective on the benefits of having multiple specialists available to provide comprehensive care to patients.

The associate clinical professor of neurology at OSU Wexner Medical Center discussed the state of interdisciplinary care for individuals with epilepsy, and how these care teams operate. [WATCH TIME: 2 minutes]

Jennifer Roggenbuck, MS, LGC, an associate professor of neurology and internal medicine at The Ohio State University Wexner Medical Center, discussed her presentation on evidence-based consensus guidelines for genetic testing and counseling from the 2022 NEALS Consortium.

Emily Harrington, MD, PhD, physician-scientist at The Ohio State University Wexner Medical Center, provided thoughts on the importance of World MS Day and the issues that plague the MS community.

The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]

Outlining the findings from a recent study comparing SAGE to the Mini-Mental State Examination, the director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center stressed the importance of identifying patients at-risk for dementia early on. [WATCH TIME: 6 minutes]

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed benefits of both the pen-and-paper and digital assessments. [WATCH TIME: 7 minutes]

The director of the Division of Cognitive and Memory Disorders at the Ohio State Wexner Medical Center discussed motivations behind creating the pen-and-paper test, as well as its digital companion. [WATCH TIME: 2 minutes]

Douglas Scharre, MD, discussed the key findings from a recent study evaluating the Self-Administered Gerocognitive Exam and its application for at-risk populations.

Douglas Scharre, MD, provided an overview of the pen-and-paper and digital versions of the test, which do not require an administrator.

Investigators also pointed to the potential repetitive administration of the SAGE test to identify stability or decline, effectively providing an objective cognitive biomarker.

As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.

The medical director of the Ohio State Sleep Medicine Institute provided insight on areas within sleep disorder care that need improvement, including the diagnostic process.

The medical director of the Ohio State Sleep Medicine Institute discussed the effect of FT218 in treating narcolepsy regardless of stimulant use, as well as its weight-related benefits it brings.

The medical director of the Ohio State Sleep Medicine Institute detailed the progress made within the sleep disorder field in recent years and where it can turn to next.

Researchers found a 70% infarct resolution and 90% motor recovery in mice injected with the EFF-nanotransfected cells.

The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed the takeaways from his lecture at ACTRIMS Forum 2021.

The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University also offered his insight on discontinuing treatment in progressive MS.

The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed his lecture at ACTRIMS Forum 2021.

The chair of the department of neurology at The Ohio State University spoke to the ongoing conversation in MS about how aggressive to be with treatment early on.

The chair of the department of neurology at The Ohio State University discussed the idea of the multiple sclerosis prodrome, presented in a plenary address at the MS Virtual 2020 meeting.

The chair of the department of neurology at The Ohio State University discussed some of the main themes and takeaways from the MS Virtual 2020 meeting.

The associate professor of clinical pediatrics and neurology at Ohio State University and section chief of pediatric neurology at Nationwide Children’s Hospital stresses the importance of broadcasting correct information to the public concerning epilepsy.

The neurosurgeon at The Ohio State University Wexner Medical Center and lead investigator of the first-in-world trial spoke about the study’s goals and the potential of the treatment.